1921
Volume 82, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

People cured from visceral leishmaniasis (VL) develop protection mediated by Th1-type cellular responses against new infections. We evaluated cytokine responses against 6 defined candidate vaccine antigens in 15 cured VL subjects and 5 healthy endemic controls with no evidence of previous exposure to parasites. Of the 6 cytokines examined, only interferon-gamma (IFN-γ) differentiated cured VL patients from non-exposed individuals, with cured patients mounting a significantly higher IFN-γ response to a crude parasite antigen preparation. Among candidate vaccine antigens tested, the largest number of cured subjects recognized cysteine proteinase B, leading to heightened IFN-γ responses, followed by sterol 24-c-methyltransferase. These two antigens were the most immunogenic and protective antigens in a murine VL model, indicating a relationship between T cell recall responses of humans cured from VL and protective efficacy in an experimental model. Further studies may help prioritize antigens for clinical development of a subunit vaccine against VL.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2010.09-0341
2010-05-01
2017-09-24
Loading full text...

Full text loading...

/deliver/fulltext/14761645/82/5/808.html?itemId=/content/journals/10.4269/ajtmh.2010.09-0341&mimeType=html&fmt=ahah

References

  1. Alvar J, Yactayo S, Bern C, , 2006. Leishmaniasis and poverty. Trends Parasitol 22: 552557.[Crossref]
  2. Haldar JP, Ghose S, Saha KC, Ghose AC, , 1983. Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect Immun 42: 702707.
  3. Carvalho EM, Badaro R, Reed SG, Jones TC, Johnson WD, Jr, 1985. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest 76: 20662069.[Crossref]
  4. Carvalho EM, Bacellar O, Brownell C, Regis T, Coffman RL, Reed SG, , 1994. Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol 152: 59495956.
  5. Holaday BJ, Pompeu MM, Jeronimo S, Texeira MJ, Sousa Ade A, Vasconcelos AW, Pearson RD, Abrams JS, Locksley RM, , 1993. Potential role for interleukin-10 in the immunosuppression associated with kala azar. J Clin Invest 92: 26262632.[Crossref]
  6. Ghalib HW, Piuvezam MR, Skeiky YA, Siddig M, Hashim FA, el-Hassan AM, Russo DM, Reed SG, , 1993. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 92: 324329.[Crossref]
  7. Basu R, Bhaumik S, Basu JM, Naskar K, De T, Roy S, , 2005. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 174: 71607171.[Crossref]
  8. Goto Y, Bogatzki LY, Bertholet S, Coler RN, Reed SG, , 2007. Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine 25: 74507458.[Crossref]
  9. Ghosh A, Zhang WW, Matlashewski G, , 2001. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 20: 5966.[Crossref]
  10. Rafati S, Zahedifard F, Nazgouee F, , 2006. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 24: 21692175.[Crossref]
  11. Stager S, Smith DF, Kaye PM, , 2000. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 165: 70647071.[Crossref]
  12. Aguilar-Be I, da Silva Zardo R, Paraguai de Souza E, Borja-Cabrera GP, Rosado-Vallado M, Mut-Martin M, Garcia-Miss Mdel R, Palatnik de Sousa CB, Dumonteil E, , 2005. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect Immun 73: 812819.[Crossref]
  13. Goto Y, Howard RF, Bhatia A, Trigo J, Nakatani M, Netto EM, Reed SG, , 2009. Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs. Vet Parasitol 160: 215220.[Crossref]
  14. Bhatia A, Daifalla NS, Jen S, Badaro R, Reed SG, Skeiky YA, , 1999. Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi . Mol Biochem Parasitol 102: 249261.[Crossref]
  15. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, Roederer M, Seder RA, , 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major . Nat Med 13: 843850.[Crossref]
  16. Cassatella MA, Hartman L, Perussia B, Trinchieri G, , 1989. Tumor necrosis factor and immune interferon synergistically induce cytochrome b-245 heavy-chain gene expression and nicotinamide-adenine dinucleotide phosphate hydrogenase oxidase in human leukemic myeloid cells. J Clin Invest 83: 15701579.[Crossref]
  17. Gantt KR, Goldman TL, McCormick ML, Miller MA, Jeronimo SM, Nascimento ET, Britigan BE, Wilson ME, , 2001. Oxidative responses of human and murine macrophages during phagocytosis of Leishmania chagasi . J Immunol 167: 893901.[Crossref]
  18. Kemp K, Kemp M, Kharazmi A, Ismail A, Kurtzhals JA, Hviid L, Theander TG, , 1999. Leishmania-specific T cells expressing interferon-gamma (IFN-gamma) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis. Clin Exp Immunol 116: 500504.[Crossref]
  19. Stager S, Maroof A, Zubairi S, Sanos SL, Kopf M, Kaye PM, , 2006. Distinct roles for IL-6 and IL-12p40 in mediating protection against Leishmania donovani and the expansion of IL-10+ CD4+ T cells. Eur J Immunol 36: 17641771.[Crossref]
  20. Nylen S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, Sacks D, , 2007. Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med 204: 805817.[Crossref]
  21. Bhaumik S, Basu R, Sen S, Naskar K, Roy S, , 2009. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major . Vaccine 27: 13061316.[Crossref]
  22. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL, , 1993. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 90: 49424946.[Crossref]
  23. Mendonca SC, De-Luca PM, Olafson RW, Jardim A, Coutinho SG, , 1994. Does lipophosphoglycan enhance the T cell-stimulatory activity of lipophosphoglycan-associated proteins? Braz J Med Biol Res 27: 553557.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2010.09-0341
Loading
/content/journals/10.4269/ajtmh.2010.09-0341
Loading

Data & Media loading...

  • Received : 18 Jun 2009
  • Accepted : 28 Jan 2010

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error